Most Read Articles
6 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
5 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

2 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.

Naltrexone 4.5 mg useful for treating fibromyalgia

31 Mar 2020

When treating fibromyalgia patients with low-dose naltrexone, the 4.5-mg dose appears to be a good choice, according to a recent study.

Researchers used the “up-and-down” method to explore dose–response relationships in using low-dose naltrexone for treating 27 fibromyalgia patients (mean age, 47 years; mean body mass index, 29.4 kg/m2). Test doses were in the range of 0.75–6 mg, with a dosing interval of 0.75 mg. The method was sequential and permitted prediction of the most effective dose in 50 percent (ED50) and 95 percent (ED95) of the patients when the dose had shifted direction 10 times.

Two patients were withdrawn from the study due to noncompliance, leaving 25 for evaluation. Of these, 11 were classified as responders, either achieving at least a 30-percent reduction in pain from baseline or having a Patient Global Impression of Improvement Scale (PGI-I) of 1–3 after 2 weeks of treatment. The dose estimates were 3.88 mg for ED50 and 5.40 mg for ED95.

When the effects on 10 common fibromyalgia symptoms were evaluated, there was a high interindividual variation seen both in the symptom presentation at baseline and in which symptoms were reduced by low-dose naltrexone. All responders had a minimum improvement of 30 percent on at least one of the 10 symptoms, but most showed a minimum improvement of 30 percent on several symptoms.

Adverse events (AEs) were common but were mostly graded as mild and tolerable, with gastrointestinal symptoms being the most commonly reported AE.

Editor's Recommendations
Most Read Articles
6 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
5 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

2 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.